| Entry |
|
|---|
| Name |
Niraparib (USAN) |
|---|
| Formula |
C19H20N4O
|
|---|
| Exact mass |
320.1637
|
|---|
| Mol weight |
320.3883
|
|---|
| Structure |
|
|---|
| Class |
Antineoplastic
DG02942 PARP inhibitor
|
|---|
| Remark |
| Product (DG03120): | D11895<JP/US> |
| Product (mixture): | D12653<US> |
|
|---|
| Efficacy |
Antineoplastic, PARP inhibitor |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors
L01XK02 Niraparib
D10140 Niraparib (USAN)
Drug groups [BR:br08330]
Antineoplastic
DG02942 PARP inhibitor
DG03120 Niraparib
D10140 Niraparib
Target-based classification of drugs [BR:br08310]
Enzymes
Transferases (EC2)
Pentosyltransferases
PARP1
D10140 Niraparib (USAN)
PARP2
D10140 Niraparib (USAN)
Drug groups [BR:br08330]
Antineoplastic
DG02942 PARP inhibitor
DG03120 Niraparib
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 24
1 C8x C 6.9300 -16.1000
2 C8x C 6.9300 -17.5000
3 C8x C 8.1424 -18.2000
4 C8y C 9.3549 -17.5000
5 C8y C 9.3549 -16.1000
6 C8y C 8.1424 -15.4000
7 C8x C 10.6864 -17.9326
8 N4y N 11.5093 -16.8000
9 N5x N 10.6864 -15.6674
10 C5a C 8.1424 -14.0002
11 O5a O 6.9132 -13.2903
12 N1a N 9.3380 -13.3098
13 C8y C 12.8800 -16.8000
14 C8x C 13.5800 -18.0124
15 C8x C 14.9800 -18.0124
16 C8y C 15.6800 -16.8000
17 C8x C 14.9800 -15.5876
18 C8x C 13.5800 -15.5876
19 C1y C 17.0800 -16.8000
20 C1x C 17.7800 -18.0124
21 N1x N 19.1800 -18.0124
22 C1x C 19.8800 -16.8000
23 C1x C 19.1800 -15.5876
24 C1x C 17.7800 -15.5876
BOND 27
1 1 2 1
2 2 3 2
3 3 4 1
4 4 5 1
5 5 6 1
6 1 6 2
7 4 7 2
8 7 8 1
9 8 9 1
10 5 9 2
11 6 10 1
12 10 11 2
13 10 12 1
14 8 13 1
15 13 14 2
16 14 15 1
17 15 16 2
18 16 17 1
19 17 18 2
20 13 18 1
21 19 16 1 #Down
22 19 20 1
23 20 21 1
24 21 22 1
25 22 23 1
26 23 24 1
27 19 24 1
|
|---|
